State of the Art Speakers
|Fay Betsou, PhD, HDR|
|Dr. Betsou is Chief Scientific Officer at Integrated Biobank of Luxembourg (IBBL), where she directs activities of the Biorefinery and Biospecimen Research Laboratory. She is a molecular biologist with 20 years of experience in molecular diagnostics, disease-oriented biobanking, biospecimen research, and certification and accreditation applied to biobanks. She holds four patents and is the author of more than 90 peer-reviewed publications, most focused on biospecimen research. She is a Past President of International Society for Biological and Environmental Repositories (ISBER), and Chair of the ISBER Biospecimen Science Working Group and the Proficiency Testing Taskforce. She is a national delegate in ISO REMCO and ISO TC276, and an Associate Professor at the University of Luxembourg.|
|Antonia M. Calafat, PhD|
|Antonia Calafat is the Chief of the Organic Analytical Toxicology Branch at the Division of Laboratory Sciences, National Center for Environmental Health of the US Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia. She earned her Bachelor, Master, and Doctoral degrees in Chemistry from the University of the Balearic Islands (Spain). Prior to her career at CDC, she was a Fulbright Scholar and a Research Associate at Emory University. She currently leads CDC’s biomonitoring programs for assessing human exposure to pesticides; polycyclic aromatic hydrocarbons; flame retardants; persistent organic pollutants such as per- and poly-fluoroalkyl substances; polybrominated diphenyl ethers; and polychlorinated dibenzo-p-dioxins, furans, and biphenyls; and chemicals added to consumer and personal-care products such as phthalates and phenols (e.g., bisphenol A, triclosan, parabens). Antonia has developed and maintained extensive collaborative research with leading scientists in the fields of exposure science, epidemiology, toxicology, and health assessment, and has co-authored more than 350 peer-reviewed publications. Her research has made relevant contributions to CDC’s biomonitoring program including the CDC’s National Reports on Human Exposure to Environmental Chemicals.|
|Antonio Hugo Jose Froes Marques Campos, MD, PhD|
|Dr. Antonio Hugo Campos is a pathologist, master and doctor in Oncology. He is currently the head of the A. C. Camargo Cancer Center Biobank in Sao Paulo, Brazil. He has served as member of the A. C. Camargo Cancer Center IRB, member of the Working Group on Biobanks for the preparation of the Ministry of Health Ordinance 2201/2011, member of the National Commission for Research Ethics (CONEP), and advisor of the Integrated Network of DNA Databanks of the Ministry of Justice.|
|Mine Cicek, PhD|
|Dr. Mine Cicek received her PhD in Genetics from Virginia Tech, Blacksburg, VA in 2001. Following a postdoctoral research fellowship at the Cleveland Clinic, Lerner Research Institute, she came to Mayo Clinic, Rochester, Minnesota in 2005 as a R25 Cancer Genetic Molecular Epidemiology Fellow. After completion of her training, she then worked in the capacity as a research associate in the Division of Experimental Pathology and Laboratory Medicine from 2006-2010, then the Division of Epidemiology, Department of Health Sciences Research from 2010-2013. She is trained as a lab-based researcher in the cancer genetic epidemiology field and has worked on multiple tumour types. She has led and published multiple studies with similar research goals on prostate, colon and ovarian cancer genetics. In 2013, she accepted the position as the laboratory director of the Biospecimens Accessioning and Processing (BAP) core laboratory, Biorepository Program, and Center for Individualized Medicine at Mayo Clinic in Rochester, Minnesota. Dr. Cicek presently is an Assistant Professor of Laboratory Medicine and Pathology in the Mayo Clinic College of Medicine and is a Senior Associate Consultant at the Mayo Clinic, Rochester, Minnesota. Her main focus is to contribute her expertise in research studies and clinical trials overseeing biospecimen collections, processing and storage. Dr. Cicek continuously tries to bring new knowledge and technology to her lab to improve on quality and best practices for biospecimens usage in biobanking. She is Mayo Clinic PI of The Alliance NCTN Biorepository and Biospecimen Resource. She is Co-PI of the Precision Medicine Initiative (PMI) All of Us (AoU) Research Program Biobank.|
|Yali Cong, PhD|
|Yali Cong was trained in Biology in Beijing Normal University and Philosophy in People’s University, China. She has been involved in research and teaching at Peking University Health Science Center (PUHSC) since she received her PhD in 1995. She teaches medical ethics to clinical medical students and supervises graduate students. After the SARS outbreak in Beijing, she and her colleagues at the school of public health in PUHSC initiated a public health ethics program. Since 2010, she has been the Chair of IRB and is working with other leaders to establish the first Human Subject Protection Program at Peking University. In 2008, she set up a joint center for medical professionalism with IMAP and the University of Columbia. She serves as the vice chair of the China Medical Ethics Association, and is a member of a number of international organizations, including WHO and IAB. She has published 50 papers in English and Chinese.|
|Georges Dagher, PhD|
|Georges Dagher, senior investigator (Directeur de Recherche) at Inserm (Paris, France) accomplished most of his career in pathophysiological and clinical research at Necker Hospital (1979-1984), College de France (1985-1993) and Faculty of medicine Broussais-Hotel Dieu (1994-2004). He joined the physiological laboratory (Cambridge, UK) for a post-doc fellowship (1983-85) and was a special guest to physiological laboratory, Harvard Medical School (Boston, US, 1982, 1984). Georges Dagher published about 100 papers in international peer-reviewed journals on hypertension, arterial hypertrophy, obesity and lipid metabolism, manic depression, renal physiology, and transmembrane ion transport. He was the director of BIOBANQUES infrastructure (Inserm US 13), a French infrastructure that regroups 85 biobanks (2012-2017); the coordinator of biological resources centres at Inserm (2006); the director of clinical research infrastructures at Inserm (2006-2009) and the deputy director of the department of clinical research at the Public Health Institute, Inserm, France (2009-2011). He participated actively to the preparatory phase of the pan-European Biobanking and Biomolecular Research Infrastructure (BBMRI-ERIC). In this preparatory phase he was a leading figure of the coordination committee and the leader of a work package on funding and financing. Later, when the infrastructure was set up as an ERIC, he was the vice chair of the Assembly of Members and member of the coordination body. He is also a member of BIOSHARE and BBMRI- LPS within the 7th EU framework program. He contributed to the OECD best practice guidelines for biological resource centres and the OECD guidelines on human biobanks and genetic databases. He participated in the elaboration of the French norm for biobanks NF S96-900 norm and the convenor of an ISO committee drafting an international standard for biobanking. He is a delegate of several French institutions to European and international committees or meetings (OECD, ESF, ERA, ALLEA, EASAC…) and a number of expert committees focusing on the issues related to biobanks within Europe and internationally. He is an expert to the Austrian Federal Ministry of science and research (BMWF) and Genome Quebec. He was also a member of the Inserm ethics committee (ERMES) and the Institutional Review Board (IRB).|
|Henrik Edgren, PhD|
|Henrik is Chief Scientific Officer at MediSapiens, with responsibility for the scientific direction of the company, as well as management of the MediSapiens data team. He obtained his PhD in cancer bioinformatics from the Faculty of Medicine at the University of Helsinki, including ground breaking work on fusion gene detection from RNA-sequencing data. He joined MediSapiens in 2013 from the Institute for Molecular Medicine Finland, where he was working on translation of sequencing results in leukemia patient care.|
|Too Heng Phon, PhD|
|Dr. Too Heng Phon received his undergraduate training in Biochemistry, Imperial College of Science & Technology, UK. He then continued with his PhD training in a joint research project at Imperial College, Institute of Ophthalmology and West Minister Hospital, London. Thereafter, he received further training with the Medical Research Council, Cambridge (UK), where he was a Procter & Gamble Fellow. He then moved to the Department of Anesthesiology and Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School where he was a recipient of the Merck Sharpe Dohme Academic Development Fellowship. Currently, he is a faculty member in the Department of Biochemistry, National University Singapore, an Adjunct Scientist in the Bioprocess Technological Institute, and a Fellow of the Singapore Massachusetts Institute of Technology Alliance (Molecular Engineering of Biological & Chemical Systems program; Chemical & Pharmaceutical Engineering program). Dr. Too is a molecular biologist focusing on biotechnology and neuroscience. In recent years, Roche Diagnostics (USA & Asia Pacific) and the National Institute of Health (USA) funded him to develop qPCR assays for infectious diseases. He is an awardee of a number of commercialization of technology grants from A*STAR and Singapore-Massachusetts Research & Technology (SMART). Dr. Too has collaborated on the co-development of IVD for prognostic/diagnostic for breast cancer. He is the founder of MiRXES in Singapore. He has intellectual property protections on specific diagnostic platforms with various research departments and with Massachusetts Institute of Technology, USA.|
|Larson Hicks is the Clinical Account Executive at Conversant Biologics, based in Huntsville, Alabama (USA), responsible for all clinical site development efforts at Conversant Bio. Prior to this role, Larson headed up Conversant's biobank consulting practice and spear-headed the 2015 Biobank Financial Sustainability Grant, a partnership with ISBER to offer a $50K grant to support business strategy planning at a biorepository struggling with financial sustainability.
Larson's background is in sales, startup consulting, product management/marketing, and concert promotion. Larson is an avid rugby fan and the proud father of five children.
|Stefan Holdenrieder, MD|
|Prof. Stefan Holdenrieder is Director of the Institute of Laboratory Medicine at the German Heart Center (DHM) of the Technical University Munich (Germany). At the DHM he has established a Biomarker Center and a Biofluid Biobank that is part of the Joint Munich Biobank (JMB). Being a specialist in laboratory medicine, his research interests are the development and comprehensive validation of new biomarkers and technologies for diagnostic applications in cardiology, oncology, immunology, neurology, and pediatrics. His special focus is spot on circulating cell-free nucleic acids, their genetic and epigenetic modifications, (exosomal) miRNA, protein and metabolomics markers as well as the development of multiparametric algorithms. His laboratory has been part of many international multicentric biomarker evaluation studies and serves as a diagnostic center for the Central European Society of Anticancer Drug Research (CESAR). Prof. Holdenrieder is secretary of the International Society of Oncological BioMarkers (ISOBM), EQA consultant for tumor marker ring trials at Instand e.V. and associate editor of several international journals.|
|Petr Holub, PhD|
|Dr. Holub is associate professor of computer science at Masaryk University. Since 2015, he has become senior IT/data protection manager with BBMRI-ERIC, European Research Infrastructure Consortium for Biobanking and BioMolecular Resources and CIO of BBMRI-ERIC common service IT. He has background both in sciences and computer science. He was head of the dept. of communication technologies at the Institute of Computer Science, Masaryk University, as well as architect of advanced multimedia and collaborative systems of the Czech national e-infrastructure at CESNET. His research in computer networks and multimedia processing has lead to more than 40 research papers in established computer science journals and ranked conferences.|
|Bartha Maria Knoppers, PhD|
|Bartha Maria Knoppers, PhD (Comparative Medical Law), is a Professor and Director of the Centre of Genomics and Policy, Faculty of Medicine, Human Genetics, McGill University.
She holds the Canada Research Chair in Law and Medicine and is the founder of the Population Project in Genomics (P3G) and CARTaGENE, Quebec’s population biobank. Chair of the Ethics Working Party of the International Stem Cell Forum (2005-2015); Co-Chair of the Sampling/ELSI Committee of the 1000 Genomes Project (2007-2014); Chair of the Ethics and Governance Council of the International Cancer Genome Consortium (2009-17 ); and Co-Chair of the Regulatory and Ethics Working Group of the Global Alliance for Genomics and Health.
Dr. Knoppers is the recipient of four Doctorates Honoris Causa, she is Fellow of the American Association for the Advancement of Science (AAAS), the Hastings Center (bioethics), the Canadian Academy of Health Sciences (CAHS) and, in 2016, was named Fellow of the Royal Society of Canada. She is also an Officer of the Order of Canada and of Quebec.
|Marike Kolossa-Gehring, PhD|
|Marike Kolossa-Gehring, Head of Section “Toxicology, Health-related Environmental Monitoring”, German Environment Agency, Germany HBM4EU coordinator. She got her PhD from the Christian-Albrechts-University Kiel. In the German Environment Agency she is in charge of the scientific lead and management of the German Human Biomonitoring Program (German Environmental Survey GerES, the German Environmental Specimen Bank ESB, the German Human Biomonitoring Commission, and the HBM cooperation between the German Chemical Industry Association (VCI) and the Federal Ministry for the Environment, Nature Conservation, Building and Nuclear Safety (BMUB)). She was involved in the development of assessment strategies and guidelines at the national, EU and OECD level and from 2006 to 2010 vice-chair and chair of the OECD Endocrine Disruptor and Assessment Task Force. She was work package leader in the EU HBM projects ESBIO, DEMOCOPHES and COPHES, the Consortium to Perform Human Biomonitoring on a European Scale preparing and piloting a European human biomonitoring study. From 2011 to 2014 Governmental Councillor of the International Society of Exposure Science (ISES).|
|Being a project manager at DIN since 2012, Dipl.-Ing. Lena Krieger is the Secretary of ISO Technical Committee 276 "Biotechnology" and its working group “Biobanks and bioresources”; she is also Secretary of the European CEN Technical Committee 140 “In vitro diagnostic medical devices”, and thus responsible for the development of medical and biotechnological standards as well as the coordination of cross-sectorial topics in these areas. She participated in the FP 7 SPIDIA project, is leading the standardization work package in the European SPIDIA4P Project, and is currently bringing the research results into European and international standardization.|
|Professor Joakim Lundeberg heads the division of gene technology, KTH based at the Science for Life Laboratory. The current research focus of Joakim relates to spatially resolved gene expression studies, spatial transcriptomics (Ståhl et al, Science, 2016), and single cell sequencing (Vickovic et al, Nature Comm, 2016). In the work recently published a method is described that allows studies of gene expression in tissue sections using RNA-sequencing to uncover transcriptional patterns in situ. Joakim also heads the National Genomics Infrastructure that has a staff of >70 full time employees which renders NGI as one of the largest sequencing centers in Europe.|
|Dr. Tohru Masui received his education and training as a developmental biologist at the University of Tokyo. He started his career as a cancer researcher at the Japanese Cancer Research Foundation (JCRF) in 1981. He then moved to the National Cancer Institute in Bethesda, USA for five years to complete his post-doc, returning to JCRF upon completion. In 1995 he moved to the Cellbank at the National Institute of Health Sciences, and was involved in policy and ethics studies on the use of human materials and information in medical research. In 1999 he started to follow the planning process of the UK Biobank and related activities in the UK. He moved to the National Institute of Biomedical Innovation (NIBIO) in 2005 and from 2009, he has been chairing the Department of Bioresources Research (Japanese Collection of Research Biologicals). He also has been working in several areas of governmental committees on bioresource policies and evaluation. He retired from the NIBIO in 2014 and moved to Keio University School of Medicine, the Center for Medical Genetics, as professor. His interest stays in the area of policy and ethics of the use of human materials and information in medical research.|
|Dan Milner, MD, MSc|
|Dan Milner, MD, MSc, Chief Medical Officer, ASCP: Dr. Milner completed his MD at the University of Alabama School of Medicine in 2000 and his residency/fellowship in anatomic pathology/clinical pathology/microbiology at the Brigham and Women’s Hospital in 2005. Before joining ASCP, Dr. Milner spent 10 years as faculty at Harvard where he taught pathology, microbiology, and infectious disease, was the primary lead for infectious disease consultations in AP/CP, and was the recipient of numerous research grants in the areas of malaria and HIV. In addition to these accomplishments, Dr. Milner began working in Africa in 1997 as a medical student and has built an international reputation as an expert in cerebral malaria. In parallel with this, he has been heavily involved in pathology capacity building in many countries and, most notably, lead the team that built an anatomic pathology laboratory in Rwanda and Haiti for advance cancer diagnostics. In his current role, he serves as the Director for the Center for Global Health at ASCP, leads all PEPFAR activities with ASCP (lab strengthening, x 5+ countries), and leads the Cancer Diagnosis and Treatment in Africa Initiative (telepathology, 20+ countries). Dr. Milner is the author of over 100 publications and has presented nationally and internationally on his work in more than 15 countries.|
|Derick Mitchell, PhD|
|Derick Mitchell, PhD is the Chief Executive of IPPOSI – the Irish Platform for Patient Organisations, Science and Industry. IPPOSI (www.ipposi.ie) is a unique, patient-led partnership between patient groups, scientists, clinicians, industry and other key decision makers, which builds consensus on issues relevant to all involved in delivering health innovations to people with unmet medical needs. Derick has over ten years experience of working in patient engagement, scientific communications, multi-stakeholder management and advocacy at both the national and European level. From 2011-2015, Derick was Communications Manager of the EU Joint Programme – Neurodegenerative Disease Research (JPND). Derick leads IPPOSI’s participation in EUPATI - a unique initiative to develop an EU-wide Patient Training Academy. He is also a board member of the Health Informatics Society of Ireland, the eHealth Ireland committee, the Medical and Life Sciences Committee of the Royal Irish Academy as well as the oversight group on implementation of the National Rare Disease Plan for Ireland. Derick graduated with a BSc (Hons) in Biotechnology from NUI Galway (2000) followed by a PhD in Molecular Medicine from University College Dublin (2004). Outside of IPPOSI, Derick spends his free time attempting to influence his two toddler daughters.|
|Keymanthri Moodley, MD, MBA|
|Keymanthri Moodley is a Professor in the Department of Medicine and Director of the Centre for Medical Ethics and Law, Department of Medicine, Faculty of Health Sciences, Stellenbosch University. In 2017, she was appointed Adjunct Professor, Department of Social Medicine, University of North Carolina-Chapel Hill, USA. Keymanthri is a family physician who currently works as a bioethicist. In 2013 she was rated by the National Research Foundation (NRF) as an established researcher based on her numerous national and international publications, conference presentations, her role on national bodies like the MRC Board and the National Health Research Ethics Council (NHREC), and her involvement in international organisations such as the World Health Organisation (WHO), International AIDS Society (IAS), and NIH DSMBs. She has worked as principal investigator on clinical trials since 1999, and served on the University Research Ethics Committee (REC) for 10 years. The Centre that she has directed for the past 14 years was designated as a Collaborating Centre in Bioethics by the WHO, one of seven in the world and the first on the African continent. The main activities of the Centre include bioethics teaching, empirical research in bioethics and clinical ethics consultation. Since 2011, Keymanthri has co-hosted an NIH Fogarty program to develop capacity in Health Research Ethics in Africa in collaboration with the Bioethics Center, University of North Carolina-Chapel Hill, USA. This program has graduated 40 postgraduate scholars from 10 African countries over the past 4 years. In 2013 she was awarded a second NIH grant to examine the ethical and social issues associated with HIV Cure research. In 2015 the Centre was awarded its third NIH grant to explore ethical, legal, and social issues related to genomic biobanking. Keymanthri is a member of the Academy of Science in South Africa. She completed an Executive MBA in 2015. Since November 2016 she has chaired the REC of the South African Medical Research Council and qualified as an Associate Executive Coach in the same year. In 2017 she was awarded her 4th NIH grant to develop a Leadership Program in Bioethics. This will include a doctoral program in Clinical and Research Ethics – the first NIH funded program of its kind based in Africa. Keymanthri was recently appointed as a member of the Scientific Advisory Committee of the European and Developing Countries Clinical Trials Program (EDCTP). She has 2 sons, Kehar (25) and Nikhal (20). In her leisure time she enjoys gardening, dancing, and mindfulness practices.|
|Helen Moore, PhD|
|Dr. Helen Moore leads the NCI Biorepositories and Biospecimen Research Branch (BBRB). As Chief she sets the direction and strategic vision for the Branch and oversees a complex set of projects related to biobanking, including: The NCI Best Practices for Biospecimen Resources, a foundational document for biobanking in use internationally; a biospecimen science research program to develop the evidence for biospecimen best practices; the Biospecimen Research Database, a web-based biospecimen science literature database; research in the ethical, legal, and social implications of biobanking; and biobanking operations for major NCI and NIH programs including the NIH Genotype-Tissue Expression (GTEx) Program. Dr. Moore previously led BBRB's Biospecimen Research Network (BRN). She speaks internationally about BBRB and biobanking, publishes articles related to BBRB and related initiatives, and serves as expert reviewer and member of advisory boards. Dr. Moore is a molecular biologist with a broad background in research and development. She came to the NCI from Celera Genomics. Dr. Moore earned her doctorate at Cornell University and her BA at Wellesley College.|
|Margaretha Persson, RN, MSc, PhD|
|Margaretha Persson is associate professor in Cardiovascular Epidemiology at the University of Lund since 2016 and is co-principal investigator of SCAPIS. She is also head of the clinical research unit at Malmö University Hospital since 2002.
She is a registered nurse with a master degree in public health, and gained her PhD in Cardiovascular Epidemiology in 2008.
|Philip Quinlan, PhD|
|Dr. Philip Quinlan has developed a career in data systems for biomedical research and is currently the Chief Technology Officer at the Advanced Data Analysis Centre (ADAC) at the University of Nottingham. ADAC provides data analytical expertise to the research and commercial sectors as a core service within the University. A flagship project of ADAC is to provide the leadership of the UKCRC Tissue Directory and Coordination Centre (BBMRI.uk) and Dr. Quinlan is the Director. The main output from this project is the development of the UKs first tissue directory that is cross-disease and also is a requirement of favourable ethical permission. Dr. Quinlan has become the Director of the UKCRC Tissue Directory and Coordination Centre having worked on database and operational systems to support biobanks since his graduation in Applied Computing in 2004. His current interest is in understanding and developing strategies for biobanks to respond to increasing data-oriented requirements.|
|Nilsa C. Ramirez, MD, FCAP|
|Nilsa C. Ramirez, MD, FCAP is the advisor and former chair of the College of American Pathologists Biorepository Accreditation Program (CAP BAP) Committee, regional commissioner of the CAP BAP, and a member of the CAP Surgical Pathology Committee. She is a pathologist, Director of the Biopathology Center and of the Autopsy Division at Nationwide Children’s Hospital, and a professor of clinical pathology at the Ohio State University in Columbus, OH, USA. Her expertise includes biobanking in the context of adult and pediatric cancer clinical trials.|
|Peter Riegman is a molecular biologist heading the Erasmus MC Tissue Bank, where fresh frozen tissue and pathology archival FFPE materials for medical research under secondary use is available according to ISO 15189:2012 standards. He was involved in the European projects: EurocanPlatform (WP leader of Biobanks), BIOPOOL, SPIDIA, BBMRI, EuroBoNeT and coordinated the TuBaFrost project 2003-2006. He was co-opted board member and chair of the OECI working group biobanking 2006-2010. In 2008 Peter became ISBER president-elect, and 2009-2010 ISBER president, followed by past president until 2011. At the end of 2010 he was elected vice president of ESBB (ISBER chapter) to become president in 2011, when he also became section editor in the editorial board of Biopreservation and Biobanking and member of the international steering committee of P3G. From 2012 he became UMC-coordinator for the pearl string initiative for Erasmus MC. That same year he joined through NEN the CEN/TC140WG3 and ISO/TC212WG4 to write sample technical standards, now implemented together with BBMRI-ERIC.|
|Michael Roehrl, MD, PhD|
|Dr. Roehrl is a practicing academic pathologist and physician scientist. He is Director of the newly created Precision Pathology Center at Memorial Sloan Kettering Cancer Center. Dr. Roehrl obtained his MD degree from the Technical University of Munich, Germany, and holds a PhD in Biological Chemistry from Harvard University.
Dr. Roehrl trained at Massachusetts General Hospital in Boston and is dually board-certified in both anatomic pathology and laboratory medicine. Dr. Roehrl has held faculty positions in Boston and Toronto before moving to his current position in New York. Dr. Roehrl's research lab focuses on biomarker discovery in solid tumors, in particular, colorectal and pancreatic cancer, using a variety of biochemical, biophysical (mass spectrometry), and computational approaches. In 2017, Dr. Roehrl became site PI for the NCI CPTAC proteogenomics consortium.
|Hugo Alberto Barrera Saldaña, PhD|
|Dr. Hugo Alberto Barrera Saldaña is a self-formed biochemist at the Autonomous University of Nuevo León, Mexico with a PhD in biomedicine from the University of Texas, USA and post-doctoral at the University of Louis Pasteur in Strasbourg, France.
He has been a member of the National System of Researchers since its foundation in 1984, and at its highest level since 1996. He is the founder of the UANL research units ULIEG, UDM, and UBM, and the post-graduate degree of the department of biochemistry, the biotechnology course of the biological sicences and the Center for Technology Transfer, as well as the Center and postgraduate in genomic biotechnology of IPN.
Dr. Barrera Saldaña has more than 200 scientific publications and almost 3,000 citations, three books, two patents, has led or codirected a hundred post-graduate theses, and has successful links with companies.
|Chen-Yang Shen, PhD|
|Prof. Chen-Yang Shen currently is a research fellow/professor in Academia Sinica. During his academic career, he was appointed as the deputy director of the Institute of Biomedical Sciences, Academia Sinica (2011-2013). Since 2005, he has been involved in the Taiwan Biobank, a national project aiming at the establishment of national cohorts of chronic diseases in Taiwan, and he is now the Chief Executive of Taiwan Biobank (since 2008). Currently, Prof. Shen also serves as the President of the Taiwan Epidemiology Association. Prof. Shen has dedicated himself to molecular and genomic epidemiological research on breast cancer for 25 years. His discoveries of multiple breast cancer susceptibility genes have resulted in the invitation, made by one of the most active international consortium of breast cancer research in the world (i.e. the Breast Cancer Association Consortium) to Prof. Shen’s lab, and joint publication of more than 25 papers in the field of genome-wide association study of breast cancer. Furthermore, Prof. Shen has been known as an expert of DNA repair. He has identified novel interactions between different DNA checkpoint/repair mechanisms, and the signalling pathway to explain breast tumorigenic contribution of the fibroblast growth factor. Recently, Prof. Shen has attempted to translate his academic works into public health practice and personalised medicine. In two publications in NEJM (2011) and BMJ (2015), he led Taiwanese teams to demonstrate the clinical feasibility to prevent adverse drug reaction by pre-screening specific HLA alleles of patients. These two studies have been considered excellent examples of precision medicine.|
|Daniel Simeon-Dubach, MD, MHA|
|Daniel Simeon-Dubach, MD, MHA is the owner of Medservice, a biobanking consulting and service company located in Walchwil, Switzerland. He earned both his MD and his Master of Health Administration (MHA) from the University of Bern, Switzerland. He has been in biobanking for more than 10 years. His research and publication focus is in biobank sustainability, biomedical reproducibility, process and quality management, as well as collaboration between academia and industry. He has co-organized and co-chaired a series of symposia on sustainability at different ISBER annual meetings. He has conducted several surveys amongst biobankers on issues of collaboration and on sustainability.
He is in the marketing committee for the GBW 2017 in Stockholm. He is chair of ISBER Standards Advisory Committee. He has served on the ISBER program committees over the past few years and is a member of the ISBER program committee for 2018. He is section editor for biobanking management of the journal Biopreservation and Biobanking and member of the editorial board of the journal Synergy.
|Tobias Sjöblom is a professor in cancer genetics at Uppsala University, Sweden. His research interests center on the acquired mutations that cause colorectal cancer and their applications in diagnostics and therapeutics. He is Program Director for U-CAN, a longitudinal cancer biobank serving academic and corporate research encompassing >12.000 patients (www.u-can.uu.se). He has a leading role in the coming national biobank infrastructure Biobank Sweden.|
|Peter Watson, MB, BChir, FRCPC|
|Peter Watson, MB, BChir, FRCPC, is Professor of Pathology and Staff Pathologist and Senior Scientist at the BC Cancer Agency, British Columbia, Canada. He is the Director of Biobanking and Biospecimen Research Services (BBRS) which is a research infrastructure group that encompasses an active biobank and biobanking support unit (Tumour Tissue Repository (BCCA-TTR) at the BC Cancer Agency and Office of Biobank Education and Research (UBC-OBER) at the Department of Pathology, University of British Columbia). Our goals are to support the establishment of small and large biobanks for biospecimen based translational research and promote access, quality, and standardization through delivery of education and training and communication of best practices. He also leads the Canadian Tissue Repository Network (CTRNet) and is deputy editor for Biopreservation and Biobanking, the journal of the International Society for Biological and Environmental Repositories (ISBER). Over the past 30 years he has maintained an active clinical pathology practice focused on breast cancer and a research laboratory program focused on elucidating mechanisms of progression, understanding the intratumoral immune response, and identifying biomarkers to guide response to therapies in breast cancer. He is author of over 180 research and biobanking publications.|
|Kurt Zatloukal, MD|
|Kurt Zatloukal, MD, is professor of pathology at the Medical University of Graz, Austria. His research focuses on molecular pathology of diseases as well as biobanking and related data management technologies. He coordinated the preparatory phase of the European Biobanking and Biomolecular Research Infrastructure (BBMRI-ERIC) and is director of the Austrian national node of BBMRI. He is also coordinator of a national digital pathology infrastructure, which is linked to biobanks. He is member of the Academia Europaea, has published 213 scientific papers, and was co-inventor of 25 patent applications.|